Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2

• Published in: iScience 2022-08, Vol.25 (8), p.104847-104847, Article 104847
• Main Authors: Irure-Ventura, Juan, Belmar-Vega, Lara, Fernández-Fresnedo, Gema, González-López, Elena, Castro-Hernández, Carolina, Rodrigo-Calabia, Emilio, Heras-Vicario, Milagros, Ruiz San Millán, Juan Carlos, López-Hoyos, Marcos
• Format: Article
• Language: English
• Subjects: Clinical finding; Disease; Health sciences
• ISSN: 2589-0042; 2589-0042
• DOI: 10.1016/j.isci.2022.104847

Different immune-mediated diseases have been described after SARS-CoV-2 vaccination, with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) being one of the possible side effects. In this study, a total of 35 patients presented ANCA for the first time during 2021, with the number during 2019 being 15. Twenty-seven out of thirty-five patients developed ANCA after vaccination. Two of them developed these antibodies after receiving the first dose (7.4%), and 25 patients developed ANCA after the second dose of the vaccine (92.6%), with BNT162b2 being the main vaccine received by these patients. In 97.1% of the patients who developed ANCA during 2021, the positivity of ANCA was accompanied by systemic involvement, with renal and respiratory tracts being the main organs affected. Therefore, an increase in the development of AAV has been observed during 2021 in comparison with 2019, which could be due to the administration of SARS-CoV-2 vaccine. [Display omitted] •The development of ANCA and AAV could be one of the side effects caused by vaccination•Incidence of new ANCA positive patients in 2021 has increased in comparison with 2019•An increase in the frequency of anti-PR3 antibodies during 2021 has been observed•A predominance of respiratory manifestations has been observed in AAV during 2021 Health sciences; Clinical finding; Disease